Hanmi Science Co., Ltd.
008930.KS
Updated: 24/09/2026, 05:06:39
Hanmi Science Co., Ltd. operates through its subsidiaries to produce and distribute pharmaceutical products both within South Korea and internationally. The company's research and development initiatives primarily target treatments for diabetes and various types of cancer. Its extensive product line further includes active pharmaceutical ingredients, general therapeutic drugs, nutritional supplements, and a variety of health-related goods and services. Additionally, it manages an online pharmacy platform and provides automated systems for pharmaceutical administration. The firm, which was initially established as Hanmi Holdings Co., Ltd. in 1973, adopted its current name, Hanmi Science Co., Ltd., in March 2012, and its corporate headquarters are situated in Seoul, South Korea.
No summaries found.
- Share price
- ₩52,100
- Market cap
- ₩3.53T
- Exchange
- KSC
- Currency
- KRW
- CEO
- Jong-Hoon Lim
- Employees
- 489
- IPO date
- 29/09/2005
- Beta
- 0.453
- Last dividend
- ₩0
- Day range
- ₩51,000 – ₩53,400
- 52-week range
- ₩25,600 – ₩61,000
- 1-day performance
- 2.76%
- 1-year performance
- 103.52%
- Current drawdown (1Y)
- -14.59%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- KR7008930000
- Created
- 07/09/2026, 05:16:03
- Last update
- 24/09/2026, 05:06:39
Track Hanmi Science Co., Ltd. with an AI analyst
See which prediction-market events move 008930.KS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.